NCT03921671 2024-05-29
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
Clinical Trials
4 trialsNCT04040361 2022-04-06
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
National Cancer Center Hospital East
Phase 2 Unknown
NCT04632459 2022-03-11
Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Unknown
NCT03966118 2019-06-03
AIO-STO-0218
Charite University, Berlin, Germany
Phase 2 Unknown